Items Tagged ‘high-risk’

October 24th, 2016

Yervoy® Improves Overall Survival in Fully Resected Stage III Melanoma Patients


Results were presented during the 2016 European Society for Medical Oncology Congress demonstrating that Yervoy® (ipilimumab) compared to placebo improves survival in stage III melanoma patients who are at high risk of recurrence following complete surgical resection. In the study, Yervoy compared with placebo significantly improved overall survival (OS) with five-year OS rates at 65.4% […]

View full entry

Tags: 2016, advanced melanoma, ESMO, high-risk, ipilimumab, Melanoma, News, overall survival, stage III, Stage III Melanoma, Yervoy

April 9th, 2015

Unituxin® Approved for Treatment of Children with High-Risk Neuroblastoma


The U.S. Food and Drug Administration (FDA) has announced the first-ever drug approval for the treatment of children with high-risk neuroblastoma. In clinical trials Unituxin® (dinutuximab) has improved survival among children with this type of cancer who have responded to previous treatment. Neuroblastoma is a type of cancer that develops in the nerve tissues of […]

View full entry

Tags: children, dinutuximab, FDA approval, high-risk, Neuroblastoma, News, Unituxin